Despite major advances, real-world data show diminishing survival outcomes and treatment-limiting toxicities in second line ...

AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the ...

Zanubrutinib shows superior progression-free survival in chronic lymphocytic leukemia compared with acalabrutinib plus ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

SEC Filings Published 06/06/2025, 08:05 AM 0 astrazeneca’s calquence receives eu approval for 1l cll treatment AZN 0.22% AZN ...

AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the European Commission (EC) to treat chronic lymphocytic leukaemia (CLL) in the ...

Calquence (acalabrutinib) is a prescription oral tablet that treats certain blood cancers in adults. Learn about dosage, side effects, and more.

Calquence is not currently approved for the treatment of MCL in Japan. As part of an extensive clinical development programme, Calquence is currently being evaluated as a single treatment and in ...

Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line mantle cell lymphoma Recommendation based on ECHO Phase III trial results ...

Calquence is not currently approved for the treatment of MCL in Japan. As part of an extensive clinical development programme, Calquence is currently being evaluated as a single treatment and in ...

Calquence (acalabrutinib) is a brand-name oral tablet prescribed for certain cancers in adults. Calquence has interactions with some other drugs and certain supplements. Examples include certain ...

Calquence, an inhibitor of Bruton tyrosine kinase, is also indicated for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. It is supplied as 100mg tablets.